EGFR+ Lung Cancer
Latest News
Latest Videos
More News
Sequential afatinib followed by osimertinib has demonstrated a long-term overall survival of close to 4 years in patients with non–small cell lung cancer who have <em>EGFR </em>deletion 19–positive tumors and acquired T790M mutations, according to interim results released from the real-world GioTag study.
Nivolumab demonstrated long-term survival benefit in heavily pretreated patients with advanced melanoma, renal cell carcinoma, and non–small cell lung cancer, according to an analysis of 5-year results from the CA209-003 trial. The analysis also identified favorable and adverse factors associated with survival that could inform future use of nivolumab.
EGFR tyrosine kinase inhibitors have remained the frontline standard of care for patients with <em>EGFR-</em>positive non–small cell lung cancer. The most commonly used EGFR TKI in the frontline setting in the United States is osimertinib, Heather Wakelee, MD, said during a presentation at the 2019 International Lung Cnacer Congress.
Nivolumab in combination with a low dose of ipilimumab demonstrated an improvement in overall survival compared with chemotherapy in patients with newly diagnosed non–small cell lung cancer whose tumors have PD-L1 expression ≥1%.
The results of the phase III PACIFIC trial made a significant impact on the treat­ment landscape for locally advanced non−small cell lung cancer when both the progression-free survival and overall survival results were announced separately.
The FDA has approved an update to the durvalumab label for patients with unresectable, stage III non–small cell lung cancer whose disease has not progressed following concurrent platinum-based chemoradiotherapy in order to include overall survival data from the phase III PACIFIC trial.<br />
Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing as a biomarker to predict response and progression-free survival rates in patients with non–small cell lung cancer receiving pembrolizumab monotherapy. The data were presented during the 2019 ASCO Annual Meeting.
Advances in targeted therapies show encouraging activity as treatment for tough-to-target driver alterations in non–small cell lung cancer emerge, according to data presented at the 2019 ASCO Annual Meeting. The discovery of additional oncogenic drivers and promising targeted therapies means that certain patients will receive treatments that produce favorable outcomes based on their disease characteristics.
The combination of erlotinib and ramucirumab showed better progression-free survival in patients with newly diagnosed <em>EGFR</em>-mutant metastatic non–small cell lung cancer compared with erlotinib plus placebo, based on findings from the RELAY trial presented during the 2019 ASCO Annual Meeting.
In an interview with Targeted Oncology, James Chih-Hsin Yang, MD discussed the updated findings from the FLAURA trial, which confirmed durable responses with frontline osimertinib in patients with EGFR-positive NSCLC. He highlighted what areas research will be focusing on in the coming years for patients harboring EGFR mutations.
The FDA has granted an orphan drug designation to durvalumab (Imfinzi) for the treatment of patients with small cell lung cancer (SCLC).<br />
In an interview with Targeted Oncology, David Spigel, MD, discussed the updated findings from the PACIFIC trial and how these data will impact the treatment landscape for patients with stage III NSCLC, as well as those with earlier-stage disease. He also highlighted controversies that clinicians face with incorporating immunotherapy into their practice for patients.
Treatment with erlotinib significantly extended progression-free survival in patients with stage IIIA-N2 <em>EGFR-</em>mutant non–small cell lung cancer compared with a combined chemotherapy regimen of gemcitabine plus cisplatin, according to clinical trial results published recently in the <em>Journal of Clinical Oncology</em>.
Biomarker expansion has enjoyed a boom since 2006, with patient incidence of positive biomarkers reaching up to 50% in non–small cell lung cancer and melanoma and 25% in acute myeloid leukemia and myelodysplastic syndromes, according to the <em>Global Oncology Trends 2018</em> report.
A new study shows comparability between liquid biopsy and tissue biopsy in both diagnostics and monitoring of non–small cell lung cancer (NSCLC). However, based on the results, liquid biopsies may be preferable to help oncologists make swifter decisions that help manage the disease.<br />